Trabectedin (Yondelis)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.[1][2][3]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: ET-743
  • Brand name: Yondelis

References

  1. 1.0 1.1 1.2 Trabectedin (Yondelis) package insert
  2. Trabectedin (Yondelis) package insert (locally hosted backup)
  3. Yondelis manufacturer's website
  4. Trabectedin (Yondelis) patient drug information from manufacturer
  5. Trabectedin (Yondelis) patient drug information (Chemocare)
  6. Trabectedin (Yondelis) patient drug information (UpToDate)